ADH-5™ (Multiplex IHC)
Simplifying the interpretation of five challenging breast diseases in one easy test.
ADH-5 breast marker multiplex IHC is composed of CK5/14 + p63 + CK7/18 antibodies. This multiplex IHC product can assist with the diagnosis of a range of breast cancer indications: Invasive versus noninvasive breast lesions can be easily distinguished by the presence or absence of myoepithelium (CK5/14 and/or p63, DAB) and glandular staining of breast cancer with CK7/18 (Fast Red). ADH-5 can clearly differentiate hyperplasia of the usual type from atypical hyperplasia, and identifies microinvasion and basal phenotypes in breast cancer.
Luminal or cytoplasmic staining may also be observed with CK5/14 and/or CK7/18 bimodal staining. For a basal-phenotype classification only CK5/14 (DAB) luminal staining is observed. Breast cancer with bimodal and/or basal-like staining is associated with poor prognosis.
Uro-3 Triple Stain™ (Multiplex IHC)
Uro-3 triple stain enables differentiation of urothelial carcinoma in situ (CIS) from reactive atypia of the urothelium. For reactive atypia or marked atypia, CD44 (blue) shows increased reactivity in all layers of the urothelium and is often absent in neoplastic cells. CK20 and p53 staining are identical to that seen in normal urothelium. In cases of CIS, diffuse, strong cytoplasmic reactivity for CK20 (FR) and diffuse nuclear reactivity for p53 (DAB) is observed in the urothelium.
SPOT-Light® HER2 CISH Kit
Combining the accuracy and objectivity of in-situ hybridization with the Ease of IHC
The SPOT-Light® HER2 CISH Kit is FDA approved as an alternative for IHC or FISH methods. The novel chromogenic ISH (CISH) technology allows for a simplified interpretation scheme compared to both IHC and FISH methods. Several studies have demonstrated that gene amplification tests provide higher correlation to Herceptin® response compared to IHC methods.
CD133 (Stem Cell Marker)
CD133, also known as Prominin 1, is expressed in endothelial progenitor cells, neuronal stem cells, glioblastoma, glial stem cells and some normal tissues such as kidney and brain. According to the cancer stem cell hypothesis, CD133-positive cells determine long-term tumor growth and therefore are suspected to influence clinical outcome. BRCA-1 breast tumors have been shown to contain distinct CD133+ cells with cancer stem cell characteristics.
CD163 (Macrophage Specific Marker)
CD163 is used to identify cells of monocyte/macrophage lineage in normal and neoplastic conditions. CD163 also identifies perivascular macrophages. Compared with CD68, studies have shown that CD163 demonstrates greater specificity as a marker of disorders of monocyte/macrophage origin. However, immunohistochemical evaluation of CD163 expression is not as sensitive for determining monocytic differentiation of AMLs or myeloid sarcoma.
Epidermal Growth Factor Receptor (Phosphorylated EGFR)
This antibody detects phosphorylated EGFR on Tyrosine 1068 of the mature human isoform that corresponds to Y1092 from the precursor form P00533-1(p170). Over-expression of EGFR has been reported in tumors of breast, lung, colon, cervix, ovary, esophagus and endometrium. This phosphorylated EGFR marker may prove to have stronger predictive value when compared to the
non-phosphorylated form.
Factor XIIIa (Far superior to polyclonals)
Factor XIIIa can be used for histiocytic phenotyping and has been reported to mark capillary hemangiomas and tumors of the central nervous system. Factor XIIIa has also been used with CD34 to differentiate between dermatofibroma and dermatofibrosarcoma protuberans. This antibody provides superior staining intensity and specificity when compared to polyclonal Factor XIIIa antibodies.
GCDFP-15 + Mammaglobin (Multiplex IHC)
Mammaglobin is expressed in 50-60% of breast cancers while GCDFP-15 is expressed in approximately 20-25%. Mammaglobin is the more sensitive marker for breast carcinoma; however, it lacks the specificity of GCDFP-15. The combination of GCDFP-15 and Mammaglobin, along with other markers, help to establish a more accurate interpretation of metastatic breast carcinoma.
Nerve Growth Factor Receptor (NGFR)
NGFR is a useful immunohistochemical marker when used in conjunction with S100 for the diagnosis of desmoplastic and neurotropic malignant melanomas. NGFR is also expressed in Schwann cells, neuronal axons and perineural cells as well as tumors derived from those cells, including malignant peripheral nerve sheath tumors.
Pan Melanoma + Ki-67 (Multiplex IHC)
This multiplex stain can distinguish melanocytotic nevi that mimic melanoma. In general, a higher proliferative population is seen in melanoma than in melanocytic nevi. There are many types of nevi, and some simulate melanoma closely. In this multiplex IHC, very low Ki-67 (DAB) labeling rate in MART-1/Tyrosinase positive cells (Fast Red), favors benignity. A high rate, especially toward the deep part of a melanocytic lesion indicates malignancy.
Synaptophysin (Superior to polyclonal)
This monoclonal antibody [clone 27G12] is a reliable marker for neuroendocrine and neuronal neoplasms. This new clone is very specific and provides sharper staining when compared to other rabbit synaptophysin antibodies. In-house studies, reference laboratories, European institutions and Nordic QC have validated this antibody as a first line screener for neuroendocrine tumors.
Smoothelin
Smoothelin is a novel cytoskeletal protein and is exclusively found in smooth muscle cells (SMC). Cells with SMC-like characteristics, such as myofibroblasts and myoepithelial cells, as well as skeletal and cardiac muscle do not contain smoothelin. Smoothelin is exclusively expressed in fully differentiated (contractile) smooth muscle cells such as human detrusor and in the human muscularis propria. Studies have also indicated smoothelin as a potential tool in the pathologic staging of invasive urothelial carcinoma, overactive bladder, and in the evaluation of atherosclerotic lesions.
Ordering Information
| Name | Concentrate | Predilute | intelliPATH FLX | Datasheet |
| ADH-5 | N/A | PM360 DS AA, H | IP360 G10 |
Datasheet |
| CD30 (Ki-1) | CM346 A, B, C | PM346 AA, H | IP346 G10, G20 | Datasheet |
| CD31 (PECAM-1) | CM347 A, B, C | PM347 AA | N/A | Datasheet |
| CD133 | CP348 A, B, C | PP348 AA | N/A | Datasheet |
| CD163 | CM353 AK, BK, CK | PM353 AA | N/A | Datasheet |
| EGFR, phosphorylated | CME300 AK, BK | PME300 AA | N/A | Datasheet |
| Factor XIIIa | CM357 AK, BK, CK | PM357 AA | IP357 G10 | Datasheet |
| GCDFP-15 + Mammaglobin | N/A | PM317 DS AA | IP317 DS G10 | Datasheet |
| Nerve Growth Factor Receptor | CME369 A, C | PME369 AA | N/A | Datasheet |
| Pan Melanoma + Ki-67 | N/A | PM362 DS AA, H | N/A | Datasheet |
| Smoothelin | CM372 A, C | PM372 AA | N/A | Datasheet |
| SPOT-Light HER2 CISH | Cat. No. INHC0001 | |||
| Synaptophysin | CM371 AK, CK | PM371 AA | IP371 G10 | Datasheet |
| Uro-3 Triple Stain | N/A | PM370TS AA | N/A | Datasheet |
